Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448502 | 1.00 | NPC1 (0.54) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL12547915 | 0.97 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL571211 | 0.97 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL204402 | 0.97 | NPC1 (0.58) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL29666029 | 0.91 | LMNA (0.56) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL23247917 | 0.89 | SMN1; SMN2 (0.53) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL11910976 | 0.88 | NPC1 (0.60) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL14845515 | 0.88 | NPC1 (0.60) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL19789881 | 0.87 | LMNA (0.60) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL883239 | 0.87 | NPC1 (0.59) | NPC1ALDH1A1SMN1; SMN2LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2010094977-A1 | NOVEL BIPHENYL COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | NR1H4, HAVCR2, CYP3A4 | NPC1 764/4885ALDH1A1 1071/4885SMN1; SMN2 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.